Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

Bridging Clinical Signs and Biological Evidence to Transform MS Diagnosis: Marcello Moccia, MD, PhD

Articles

A new study highlighted the importance of initiating immunotherapy promptly in chronic inflammatory demyelinating polyneuropathy to prevent axonal damage and disability progression.

Early Immunotherapy May Be Crucial to Prevent Axonal Damage in CIDP, Study Suggests

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

Navigating the Decision to Treat Multiple Sclerosis Early Versus Later: Mikael Cohen, MD

Here's some of what is coming soon to NeurologyLive® this week. 

This Week on NeurologyLive® — January 20, 2024

The neurologist and sleep disorder specialist at Allegheny Health Network discussed the challenges with preventing narcolepsy and the strategies patients can take to improve their overall prognosis. [WATCH TIME: 4 minutes]

Curving Complications Associated With Narcolepsy: Mihaela Nowak, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed groundbreaking research on chronic pain, focusing on the discovery of new mechanisms involving nerve growth factor and its receptors.

NeuroVoices: Nigel Bunnett, PhD, BSc, on Identifying a Novel Therapeutic Target for Chronic Pain

Founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine.

The founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine talked about a recent study that estimated the lifetime risk of dementia and its implications for prevention, care, as well as societal planning. [WATCH TIME: 5 minutes]

Understanding Lifetime Risk and the Rising Burden of Dementia: Josef Coresh, MD, PhD

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Treatment Advances in Targeting Underlying Pathophysiology of Myasthenia Gravis

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Video content above is prompted by the following:

A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?

Nicholas J. Silvestri, MD, FAAN; Ali A. Habib, MD; Neelam Goyal, MD; and Katherine Ruzhansky, MD, MS, explore the multifaceted aspects of generalized myasthenia gravis, from its clinical presentation and diagnosis to emerging targeted therapies, emphasizing the importance of personalized treatment approaches, discussing recent clinical trial data, and addressing ongoing challenges in both adult and pediatric populations.

Panelists discuss how myasthenia gravis presents clinically in adults and children, factors contributing to its underdiagnosis, and symptoms that should prompt specialist consultation.

Generalized Myasthenia Gravis Presentation and Diagnosis

Panelists discuss how the classification of generalized myasthenia gravis (gMG) informs and guides treatment strategies for patients.

Generalized Myasthenia Gravis Classification and Treatment Strategy

Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).

Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

Panelists discuss how various outcome measures are utilized in clinical practice to assess and monitor patients with generalized myasthenia gravis.

Outcome Measures in Generalized Myasthenia Gravis

Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.

Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).

Panelists discuss how specific disease characteristics and individual patient factors influence their decision-making process when selecting treatments for generalized myasthenia gravis.

Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

Panelists discuss how they approach combination therapy in generalized myasthenia gravis (gMG), including patient selection and timing, while also examining how the availability of newer targeted treatments has influenced their approach to managing newly diagnosed patients.

Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.

Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.

Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.

Use of Targeted Agents in Generalized Myasthenia Gravis

Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.

Management of Generalized Myasthenia Gravis in Pediatric Patients

Panelists discuss how certain aspects of myasthenia gravis management remain challenging, identifying ongoing unmet needs in diagnosis, treatment, and patient care.

Unmet Needs in Generalized Myasthenia Gravis

Panelists discuss how emerging agents for generalized myasthenia gravis (gMG) show promise in addressing current treatment gaps, highlighting specific therapies they find particularly exciting for future management of the condition.

Generalized Myasthenia Gravis Pipeline

Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.

New Data from AANEM 2024 in Generalized Myasthenia Gravis

Panelists discuss how a multidisciplinary approach involving various specialists is crucial in managing generalized myasthenia gravis (gMG), offering final insights and recommendations for health care professionals treating gMG patients.

Clinical Pearls for Management of Generalized Myasthenia Gravis

Peer Exchange

Recent advancements in the treatment of generalized myasthenia gravis (gMG) involve agents targeting the neonatal Fc receptor (FcRn). These agents differ in their mechanisms of action, with some inhibiting FcRn to reduce pathogenic IgG levels, while others modulate immune responses. The therapeutic landscape includes both approved and investigational drugs, each with unique pharmacological profiles. Understanding these differences is crucial for optimizing treatment strategies and improving patient outcomes. The development of FcRn-targeting therapies represents a significant step forward in managing gMG, offering new hope for patients with this challenging condition.

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Key Takeaways

EP: 1.Generalized Myasthenia Gravis Presentation and Diagnosis

EP: 2.Generalized Myasthenia Gravis Classification and Treatment Strategy

EP: 3.Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP: 4.Outcome Measures in Generalized Myasthenia Gravis

EP: 5.Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP: 6.Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP: 7.Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP: 8.Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP: 9.Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 10.Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 11.Use of Targeted Agents in Generalized Myasthenia Gravis

EP: 12.Management of Generalized Myasthenia Gravis in Pediatric Patients

EP: 13.Unmet Needs in Generalized Myasthenia Gravis

EP: 14.Generalized Myasthenia Gravis Pipeline

EP: 15.New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP: 16.Clinical Pearls for Management of Generalized Myasthenia Gravis